Biology subjects

Gomez, E. C.

Publications and source records attributed to Gomez, E. C..

5 recordsLinked to original sources

bioRxiv2026

Sex Differences in DNA Methylation and Gene Expression Reveal Distinct Molecular Programs in Muscle-Invasive Bladder Cancer

Sex differences in muscle-invasive bladder cancer (MIBC) incidence and outcomes are well established, but the underlying epigenetic mechanisms remain poorly understood. We integrated genome-wide DNA methylation and RNA sequencing to define sex-associated epigenetic and transcriptional programs in human MIBC and evaluated their conservation in the N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) mouse model. Male tumors exhibited substantially broader DNA methylation remodeling, whereas female tumors showed prominent epithelial-mesenchymal transition (EMT) and mitotic programs. These sex-associated patterns were recapitulated in BBN tumors, with substantial conservation of human MIBC methylation changes and transcriptional programs. Cross-species integration identified conserved methylation-regulated genes, including ADAMTS12, ONECUT2, and PPP2R2C, whose expression increased following pharmacologic DNA demethylation and was associated with disease progression. Given the potential role of sex chromosomes in sex-associated molecular differences in MIBC, we evaluated X-chromosome inactivation escape and Y-linked gene expression. Reduced expression of an X-chromosome inactivation escape signature was independently associated with shorter overall survival, while reduced Y-linked gene expression was associated with immune activation. Together, these findings identify conserved sex-associated epigenetic programs in MIBC and demonstrate distinct methylation, transcriptional, and sex-chromosome features that may contribute to sex differences in bladder cancer biology and clinical outcomes.

cancer biology↗

bioRxiv2025

EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer

Advanced prostate cancer (PrCa) remains a leading cause of cancer-related death among men because nearly all patients progress on standard therapy that targets androgen receptor (AR) signaling. An important mechanism driving therapeutic resistance is lineage plasticity, the ability of PrCa cells to reprogram into lineage variants like neuroendocrine (NE) PrCa that no longer depend on AR signaling. The histone methyltransferase EZH2 has been implicated in PrCa lineage plasticity and EZH2 inhibitors are being evaluated clinically for the treatment of PrCa. Here we test how Ezh2 impacts the evolution of PrCa lineage plasticity using genetically engineered mice and human patient data. Reduced Ezh2 expression diversifies the evolution of PrCa lineage variants, including a newly discovered variant with high expression of neurofilament genes, in both mice and humans. Lineage variant diversification is associated with activation of Klf transcription factor programs and AR cistrome reprogramming that is normally repressed by Ezh2. These findings advance the understanding of PrCa lineage plasticity and have implications for using EZH2 as a target for PrCa therapy.

cancer biology↗

bioRxiv2025

The Th1/Th17 axis regulates chimeric antigen receptor (CAR) T cell therapy toxicities

CAR-T therapy has led to significant improvements in patient survival. However, a subset of patients experience high-grade toxicities, including cytokine release syndrome (CRS) and immune cell-associated hematologic toxicity (ICAHT). We utilized IL-2R knockout mice to model cytokine toxicities with elevated levels of IL6, IFN{gamma}, and TNF and increased M1-like macrophages. Onset of CRS was accompanied by a reduction in peripheral blood neutrophils due to disruption of bone marrow neutrophil homeostasis characterized by an increase in apoptotic neutrophils and a decrease in proliferative and mature neutrophils. Both non-tumor-bearing and E-ALL tumor-bearing mice recapitulated the co-occurrence of CRS and neutropenia. IFN{gamma}-blockade alleviated CRS and neutropenia without affecting CAR-T efficacy. Mechanistically, a Th1-Th17 imbalance was observed to drive co-occurrence of CRS and neutropenia in an IFN{gamma}-dependent manner leading to decreased IL-17A and G-CSF, neutrophil production, and neutrophil survival. In patients, we observed an increase in the IFN{gamma}-to-IL-17A ratio in the peripheral blood during high-grade CRS and neutropenia. We have uncovered a biological basis for ICAHT and provide support for the use of IFN{gamma}-blockade to reduce CRS and neutropenia. Statement of SignificanceDespite clinical success of CAR-T therapy, patients develop toxicities such as cytokine release syndrome and neutropenia, whose co-occurrence impacts their survival and quality-of-life. We recapitulate these toxicities in mice to discover their co-occurrence is driven by Th1-Th17 imbalance following CAR-T administration, which can be prevented via IFN{gamma} blockade.

cancer biology↗

bioRxiv2021

Racial differences in androgen metabolism and receptor signaling in prostate cancer

Dihydrotestosterone (DHT) and testosterone (T) mediated androgen receptor (AR) nuclear translocation initiates transcription of AR target genes that are pivotal for prostate cancer (PrCa) development and progression. Here we provide data indicating that in contrast to European American (EA) men, African American (AA) men with localized PrCa can exploit an alternative progesterone-androsterone-5-androstanedione pathway for DHT biosynthesis. Enzymes that are involved in alternate pathways of DHT biosynthesis are elevated in PrCa tissues from AA men, compared to EA men, and also correlated with increased serum DHT levels. In addition, higher serum DHT levels reflect increased RNA expression of AR target genes in PrCa tissues from AA men. Interestingly, serum T but not DHT levels are significantly lower in AA men compared to EA men with PrCa. Furthermore, serum progesterone and related intermediate metabolites levels that are produced during alternate pathways of DHT biosynthesis are significantly lower in AA men with PrCa and associated with a shorter time to disease progression. These data highlight that androgen biosynthesis is altered in therapy naive localized PrCa in AA men, and can potentially serve as prognostic indicators of disease progression. SignificanceOur work provides a rationale to examine potential pharmacological interventions that target androgen biosynthesis and AR signaling earlier in the disease continuum in AA men with PrCa. Additionally, our study lays the groundwork for developing serum measurements of intermediate androgen metabolites as PrCa prognostic biomarkers. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=147 SRC="FIGDIR/small/437727v1_ufig1.gif" ALT="Figure 1"> View larger version (24K): org.highwire.dtl.DTLVardef@932dd0org.highwire.dtl.DTLVardef@a4cca0org.highwire.dtl.DTLVardef@1764be4org.highwire.dtl.DTLVardef@1708a63_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗

bioRxiv2018

Prevention of chromatin destabilization by FACT is crucial for malignant transformation

Expression of histone chaperone FACT is increased in tumors and associated with poor prognosis. We investigated why aggressive tumor cells need FACT using a model where FACT could be turned off and confirmed that while FACT is not essential for non-tumor cells, cells become dependent on FACT following oncogene-induced transformation. We compared the phenotypic and transcriptional changes induced by FACT loss and excluded a direct role for FACT in the transcription of genes essential for the viability of transformed cells. Moreover, we established that in immortalized and transformed cells, FACT has a weak negative effect on gene expression. At the same time, we observed a positive correlation between FACT enrichment and the rate of transcription, which was consistent with previous reports. To explain these puzzling observations, we hypothesized that FACT does not facilitate transcription elongation in transformed cells, but prevents nucleosome loss associated with transcription. Indeed, we observed destabilization of chromatin in immortalized and transformed cells upon FACT loss. Furthermore, transformed cells had less stable chromatin than non-transformed cells, which made them vulnerable to FACT loss. However, the mechanisms of cell death upon chromatin destabilization needs to be established. Our data suggest that malignant transformation is accompanied by general chromatin destabilization, and FACT prevents irredeemable chromatin loss.

cell biology↗